OTLK
Outlook Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-31/100
Last price
0.60
▲ 0.03 (5.21%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.59
Prev close
0.57
Day high
0.61
Day low
0.59
Volume
2.21M
Market cap
$146.51M
P/E (TTM)
—
52W range
0.16 – 2.54
Day trading desk
Gap from prior close
+3.86%
Prior close 0.57
VWAP
0.60
+0.60% from price
Relative volume
0.16×
Quiet session
Session range
3.66%
0.59 – 0.61
Position in range
69%
Mid range
ATR (14D)
0.04
6.82% of price
Prior day high
0.62
PDH
Prior day low
0.57
PDL
Bid / ask spread
—
Quote not published
Session volume
2.21M
Avg 13.56M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+4.84%
+3.3%
1M
-6.12%
-7.2%
3M
-64.18%
-67.2%
6M
+140.72%
+126.2%
YTD
-61.91%
-75.4%
1Y
-44.79%
-60.1%
3Y
-86.57%
-167.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on OTLK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
30.77M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | KENYON LAWRENCE A. Chief Financial Officer |
BUY | 101.01K | $76.40K | Direct |
| Aug 14, 26 | JAHR ROBERT CHARLES Chief Executive Officer |
BUY | 151.51K | $114.61K | Direct |
| Aug 12, 26 | SUKHTIAN GHIATH M Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.53M | $2.50M | Indirect |
| Jul 29, 26 | SUKHTIAN FAISAL GHIATH Director |
BUY | 95.40K | $100.00K | Direct |
| Jun 2, 26 | HADDADIN YEZAN MUNTHER Director |
BUY | 29.00K | $24.14K | Direct |
| May 27, 26 | SUKHTIAN FAISAL GHIATH Director |
BUY | 122.17K | $71.53K | Direct |
| May 26, 26 | HILZINGER KURT J Director |
BUY | 400.00K | $176.52K | Direct |
| May 26, 26 | THURMAN RANDY H Director |
BUY | 5.00K | $2.15K | Direct |
| May 26, 26 | HADDADIN YEZAN MUNTHER Director |
BUY | 34.00K | $14.96K | Direct |
| May 27, 25 | SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 4.29M | $6.00M | Indirect |
| Jan 17, 25 | SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 3.46M | $7.71M | Indirect |
| Jan 17, 25 | SUKHTIAN GHIATH M Director and Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 3.46M | $8.68M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HADDADIN YEZAN MUNTHER |
Director | 66.17K | Purchase |
HILZINGER KURT J |
Director | 423.65K | Purchase |
JAHR ROBERT CHARLES |
Chief Executive Officer | 151.51K | Purchase |
KENYON LAWRENCE A. |
Chief Financial Officer | 106.96K | Purchase |
SUKHTIAN FAISAL GHIATH |
Director | 220.97K | Purchase |
SUKHTIAN GHIATH M |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
THURMAN RANDY H |
Director | 5.59K | Purchase |
Fundamentals
Market cap$146.51M
Enterprise value$146.44M
Revenue (TTM)$-1.16M
Gross profit$-2.28M
EBITDA$-55.53M
Net income$-61.12M
EPS (TTM)$-0.66
Free cash flow$-37.36M
Total cash$11.24M
Total debt$18.43M
Book value / share$-0.06
Shares outstanding243.45M
Float197.82M
Short % of float14.02%
Dividend yield0.00%
Beta (5Y)0.67
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.02
PEG ratio—
Price / sales—
Price / book—
EV / revenue-125.87
EV / EBITDA-2.64
Gross margin0.00%
Operating margin-124255.27%
Profit margin0.00%
Return on equity—
Return on assets-143.17%
Debt / equity—
Current ratio0.81
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.41M | $0 | $0 | $0 | — |
| Operating revenue | $1.41M | $0 | $0 | $0 | — |
| Cost of revenue | $1.36M | $0 | — | — | — |
| Gross profit | $57.20K | $0 | — | — | — |
| Research & development | $27.18M | $41.76M | $26.45M | $42.33M | -34.9% |
| Selling, general & admin | $39.94M | $29.94M | $26.67M | $20.74M | +33.4% |
| Total operating expense | $67.12M | $71.70M | $53.13M | $63.07M | -6.4% |
| Operating income | -$67.06M | -$71.70M | -$53.13M | -$63.07M | +6.5% |
| Net interest income | -$193.39K | -$2.25M | -$1.56M | -$1.49M | +91.4% |
| Pre-tax income | -$63.98M | -$75.36M | -$58.98M | -$66.05M | +15.1% |
| Tax provision | -$1.55M | $2.80K | $2.80K | $2.80K | -55,522.5% |
| Net income | -$62.42M | -$75.37M | -$58.98M | -$66.05M | +17.2% |
| Net income to common | -$62.42M | -$75.37M | -$58.98M | -$66.05M | +17.2% |
| Basic EPS | -1.79 | -4.06 | -4.80 | -6.20 | +55.9% |
| Diluted EPS | -1.79 | -4.06 | -4.80 | -6.20 | +55.9% |
| EBIT | -$63.69M | -$72.21M | -$56.45M | -$64.56M | +11.8% |
| EBITDA | -$63.58M | -$72.09M | -$56.40M | -$64.36M | +11.8% |
| Basic shares | 34.80M | 18.55M | 12.51M | 10.60M | +87.6% |
| Diluted shares | 34.80M | 18.55M | 12.51M | 10.60M | +87.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.08M | $14.93M | $23.39M | $17.40M | -45.9% |
| Cash & short-term investments | $8.08M | $14.93M | $23.39M | $17.40M | -45.9% |
| Accounts receivable | $1.49M | $0 | — | — | — |
| Inventory | $3.34M | $0 | — | — | — |
| Total current assets | $17.39M | $27.42M | $30.98M | $27.52M | -36.6% |
| Property, plant & equipment | $225.51K | $274.64K | $26.17K | $70.36K | -17.9% |
| Total assets | $18.58M | $28.82M | $32.30M | $28.53M | -35.5% |
| Total current liabilities | $45.81M | $42.55M | $46.73M | $19.73M | +7.7% |
| Current debt | $29.95M | $29.44M | $35.55M | $10.92M | +1.7% |
| Total debt | $30.19M | $29.74M | $35.56M | $10.96M | +1.5% |
| Total liabilities | $50.77M | $101.90M | $46.74M | $19.79M | -50.2% |
| Retained earnings | -$605.71M | -$543.28M | -$467.92M | -$408.94M | -11.5% |
| Shareholder equity | -$32.19M | -$73.08M | -$14.44M | $8.74M | +56.0% |
| Working capital | -$28.43M | -$15.14M | -$15.75M | $7.79M | -87.8% |
| Net tangible assets | -$32.19M | -$73.08M | -$14.44M | $8.74M | +56.0% |
| Shares issued | 53.89M | 23.91M | 13.01M | 11.37M | +125.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$62.42M | -$75.37M | -$58.98M | -$66.05M | +17.2% |
| Depreciation & amortisation | $117.05K | $113.86K | $44.19K | $204.69K | +2.8% |
| Stock-based compensation | $8.90M | $5.39M | $5.55M | $7.71M | +65.2% |
| Change in working capital | $4.86M | -$3.02M | $4.75M | -$1.68M | +261.0% |
| Operating cash flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | +24.7% |
| Financing cash flow | $44.98M | $60.33M | $48.97M | $59.59M | -25.4% |
| Free cash flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | +24.7% |
| End cash position | $8.08M | $14.93M | $23.39M | $17.40M | -45.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $8.70K | $127.44K | -$1.21M | -$91.79K | $1.51M | — | -93.2% |
| Operating revenue | $8.70K | $127.44K | -$1.21M | -$91.79K | $1.51M | — | -93.2% |
| Cost of revenue | $16.96K | $149.33K | $29.63K | $916.51K | $439.81K | — | -88.6% |
| Gross profit | -$8.27K | -$21.89K | -$1.24M | -$1.01M | $1.07M | — | +62.2% |
| Research & development | $3.25M | $4.50M | $3.63M | $5.98M | $7.13M | — | -27.8% |
| Selling, general & admin | $7.55M | $9.50M | $8.61M | $10.33M | $9.68M | — | -20.6% |
| Total operating expense | $10.80M | $14.01M | $12.25M | $16.31M | $16.81M | — | -22.9% |
| Operating income | -$10.81M | -$14.03M | -$13.48M | -$17.31M | -$15.75M | — | +22.9% |
| Net interest income | $7 | $3 | $0 | -$174.42K | -$49.35K | — | +133.3% |
| Pre-tax income | -$20.32M | -$4.45M | -$23.06M | -$14.85M | -$20.15M | — | -356.3% |
| Tax provision | $0 | $0 | — | -$1.55M | $0 | $2.80K | — |
| Net income | -$20.32M | -$4.45M | -$23.06M | -$13.29M | -$20.15M | — | -356.3% |
| Net income to common | -$20.32M | -$4.45M | -$23.06M | -$13.29M | -$20.15M | — | -356.3% |
| Basic EPS | -0.15 | -0.05 | -0.38 | — | -0.55 | -1.50 | -200.0% |
| Diluted EPS | -0.15 | -0.05 | -0.38 | — | -0.55 | -1.50 | -200.0% |
| EBIT | -$10.81M | -$14.03M | -$13.48M | -$14.58M | -$15.75M | — | +22.9% |
| EBITDA | -$10.80M | -$14.00M | -$13.45M | -$14.55M | -$15.72M | — | +22.9% |
| Basic shares | 136.74M | 81.84M | 60.20M | — | 36.96M | 30.87M | +67.1% |
| Diluted shares | 136.74M | 81.84M | 60.20M | — | 36.96M | 30.87M | +67.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.24M | $7.75M | $8.68M | $8.08M | $8.90M | — | +45.1% |
| Cash & short-term investments | $11.24M | $7.75M | $8.68M | $8.08M | $8.90M | — | +45.1% |
| Accounts receivable | $1.64M | $2.72M | $114.61K | $1.49M | $1.75M | — | -39.5% |
| Inventory | $5.04M | $3.34M | $3.46M | $3.34M | $4.13M | — | +50.8% |
| Total current assets | $23.17M | $20.90M | $17.17M | $17.39M | $21.10M | — | +10.8% |
| Property, plant & equipment | $185.18K | $198.97K | $212.41K | $225.51K | $238.27K | — | -6.9% |
| Total assets | $26.18M | $21.89M | $18.24M | $18.58M | $22.39M | — | +19.6% |
| Total current liabilities | $28.68M | $38.88M | $49.06M | $45.81M | $31.49M | — | -26.2% |
| Current debt | $18.23M | $15.85M | $36.66M | $29.95M | $14.00M | — | +15.0% |
| Long-term debt | — | $11.12M | — | — | $20.44M | $21.05M | — |
| Total debt | $18.43M | $27.19M | $36.89M | $30.19M | $34.70M | — | -32.2% |
| Total liabilities | $36.58M | $50.89M | $56.79M | $50.77M | $59.58M | — | -28.1% |
| Retained earnings | -$653.54M | -$633.22M | -$628.77M | -$605.71M | -$592.42M | — | -3.2% |
| Shareholder equity | -$10.39M | -$28.99M | -$38.55M | -$32.19M | -$37.19M | — | +64.2% |
| Working capital | -$5.51M | -$17.98M | -$31.89M | -$28.43M | -$10.39M | — | +69.3% |
| Net tangible assets | -$10.39M | -$28.99M | -$38.55M | -$32.19M | -$37.19M | — | +64.2% |
| Shares issued | 187.10M | 104.61M | 64.56M | 53.89M | 43.48M | — | +78.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$20.32M | -$4.45M | -$23.06M | -$13.29M | -$20.15M | -356.3% |
| Depreciation & amortisation | $13.79K | $30.42K | $30.07K | $29.74K | $29.41K | -54.7% |
| Stock-based compensation | $791.67K | $757.48K | $881.15K | $1.82M | $1.68M | +4.5% |
| Change in working capital | -$11.01M | $5.41M | -$2.37M | $1.71M | $2.19M | -303.4% |
| Operating cash flow | -$21.01M | -$7.83M | -$14.94M | -$12.38M | -$11.90M | -168.4% |
| Financing cash flow | $26.60M | $6.90M | $15.53M | $11.56M | $13.25M | +285.6% |
| Free cash flow | -$21.01M | -$7.83M | -$14.94M | -$12.38M | -$11.90M | -168.4% |
| End cash position | $11.24M | $7.75M | $8.68M | $8.08M | $8.90M | +45.1% |
Options analytics
Put / call volume
0.24
Call-heavy session
Put / call open interest
0.02
Positioning, not flow
Max pain
0.50
-16.9% from spot
ATM implied vol
400.0%
Nearest strike to spot
Skew (10% OTM)
+593.7%
Puts bid over calls
Call volume
21
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
0.50
232 contracts
Heaviest put OI
0.50
6 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | -0.09 | -20.0% |
| Mar 2026 | -0.12 | -0.17 | -43.3% |
| Dec 2025 | -0.17 | -0.22 | -26.9% |
| Sep 2025 | -0.25 | -0.29 | -17.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.08 | 2 | $2.16M | — |
| Next quarter | -0.05 | 3 | $5.30M | +539.1% |
| Current year | -0.44 | 2 | $682.67K | -51.7% |
| Next year | -0.12 | 3 | $44.07M | +6,355.6% |
Analyst targets & ownership
Mean target$5.03
High target$10.50
Low target$1.60
Implied upside734.99%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders12.64%
Held by institutions16.67%
Institutions holding82
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.61
-0.61% from price
SMA 20
0.64
-5.54% from price
SMA 50
0.73
-18.02% from price
SMA 100
0.94
-36.30% from price
SMA 200
0.72
-16.16% from price
EMA 12
0.61
-1.53% from price
EMA 26
0.66
-8.15% from price
EMA 50
0.74
-18.81% from price
RSI (14)
40.5
Neutral
MACD (12,26,9)
-0.04
Hist 0.00
ATR (14)
0.04
6.82% of price
Realised vol 30D
51.7%
Annualised
Bollinger upper
0.71
20, 2σ
Bollinger lower
0.56
20, 2σ
50 / 200 cross
Golden
0.73 vs 0.72
Trend bias
Below 200
-16.16%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.99
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
51.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-92.0%
Peak to trough
Max drawdown 5Y
-99.6%
Peak to trough
ATR 14
0.04
6.82% of price
Beta (reported)
0.67
5Y monthly, from filing
Short interest
Shares short
32.22M
Prior 19.90M
Change vs prior
+61.9%
Shorts adding
% of float
14.02%
Elevated
% of shares out
13.24%
Against total outstanding
Days to cover
2.6
Liquid
Float
197.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 11, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Aug 14, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 27, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Jul 27, 26 | BTIG | UPGRADE | Neutral | Buy |
| Jun 11, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| May 18, 26 | BTIG | DOWNGRADE | Buy | Neutral |
| Mar 11, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Feb 18, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Feb 18, 26 | Chardan Capital | MAINTAINED | Neutral | Neutral |
| Jan 5, 26 | Chardan Capital | MAINTAINED | Neutral | Neutral |
| Jan 2, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Dec 22, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateMar 18, 2019
Last split1:20
Split dateMar 14, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-30
Corporate Changes & Voting Matters
8-K · 2026-09-18
Corporate Changes & Voting Matters
8-K · 2026-08-27
Periodic Financial Reports
10-Q · 2026-08-18
Periodic Financial Reports
NT 10-Q · 2026-08-17
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-24
Headlines
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
GlobeNewswire · 1d ago
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire · 6d ago
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 183%
Barrons.com · 9d ago
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
GlobeNewswire · 26d ago
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
GlobeNewswire · 27d ago
Outlook Therapeutics Appoints Kevin Lundquist as CFO
MT Newswires · 41d ago
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
GlobeNewswire · 41d ago
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
GlobeNewswire · 41d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.